Effect of ACE Inhibitors, ARBs, and Other Antihypertensive Drugs on Hypertensive Patients with COVID-19 Infection
نویسندگان
1 1Anesthesia and Critical Care Department, Critical Care Quality Improvement Research Center, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 6 Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 7Infection Disease and Tropical Medicine Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran
4 8Department of Infectious Diseases, Imam Hossein Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran
5 2School of Medicine, Iran University of Medical Science, Tehran, Iran
6 3Cardiovascular division, Imam Hossein hospital, Shahid Beheshti University of Medical Science, Tehran, Iran
7 4Department of Internal Medicine, Imam Hossein Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran
8 5Anesthesia and Critical Care Department, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
doi
10.22037/nbm.v14i1.50109چکیده
Background: To investigate differences in disease severity and outcomes among COVID-19 patients with a history of hypertension using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other antihypertensive drugs. Materials and Methods: Based on drug exposure, 153 hypertensive patients with COVID-19 were divided into three groups: angiotensin-converting enzyme inhibitor group, angiotensin receptor blocker group, and other antihypertensive drugs group. The outcomes, laboratory and clinical results, were compared. Results: The frequency of ICU admission among patients in the angiotensin receptor blocker, angiotensin-converting enzyme inhibitor, and other antihypertensive drug groups was 25.5%, 27.8%, and 23.2%, respectively. The intubation frequency was 23.6%, 27.8%, and 30.4%, respectively. The longest hospital stay was observed in the angiotensin-converting enzyme inhibitor group, but the difference was not significant (P>0.05). The mortality rates were highest in the other antihypertensive drug groups. Conclusion: Patients with COVID-19 who consume angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have lower mortality rates compared to patients consuming other antihypertensive drugs.
